Document:

<PAGE>
                                                                   EXHIBIT 10.26

                      AMENDMENT NO. 1 OF RESEARCH AGREEMENT

         The Agreement amendments stated herein are made by and between
Antigenics, L.L.C., hereinafter referred to as Sponsor and the University of
Connecticut Health Center, hereinafter referred to as UCHC.

         The purpose of this document is to amend the Research Agreement entered
into by and between Sponsor and UCHC on February 18, 1998. All terms and
conditions agreed to in the Research Agreement shall remain in full force and
effect except for those amended by this document.

ARTICLE 3- ADDITION OF 1 SUPPLEMENT YEAR

3.       The investigation covered by this Agreement shall commence on February
         12, 1998 and shall extend for a period of 70.5 months, expiring on
         December 31, 2003.

ARTICLE 5- ADDENDUM TO ARTICLE 5

5.0A     Sponsor agrees to pay UCHC the sum of $1,200,000.00 for the project
         extension year covered by this Amendment No. 1, in accordance with
         agreed budget (see Attachment 1), payments to be made as follows:

<TABLE>
<S>                        <C>
         $300,000          Payable no later than February 15, 2003
         $300,000          Payable by no later than May 15, 2003
         $300,000          Payable by no later than August 15, 2003
         $300,000          Payable by no later than November 15, 2003
</TABLE>

<PAGE>
The Parties hereto have caused this Amendment No. 1 to be executed by duly
authorized representatives effective as of the latter date indicated below.

ANTIGENICS, L.L.C.- "SPONSOR"

   /s/ Russell Herndon                       4/19/02
----------------------------                 ---------------
                                             (Date)
Name:  Russell Herndon
Title: President, COO

UNIVERSITY OF CONNECTICUT HEALTH CENTER- UCHC

   /s/ Leonard P. Paplauskas                 4/12/02
----------------------------                 ---------------
                                             (Date)

Name:  Leonard P. Paplauskas

Title: Assoc. Vice President for Research Administration
<PAGE>
                                  ATTACHMENT 1

                                Antigenics Budget

                                   $1,200,000

<TABLE>
<CAPTION>
Sub Code                   Description                        Amount
--------                   -----------                        ------
<S>       <C>                                               <C>
1000                       Salaries & Wages                  355,000

4000                       Fringe                            128,000

2000                       Purchases Services                184,381
2162                       Travel                             35,000

3000                       Supplies/Minor Equipment          250,000
                                                           ----------

          Total Direct Costs                                 952,381

          Total Indirect Costs                               247,619
                                                           ----------

          Total                                            $1,200,000
                                                           ==========
</TABLE><PAGE>
                                                                   Exhibit 10.28

February 10, 2005

Leonard P. Paplauskas
Associate Vice President for Research Administration
University of Connecticut Health Center
Center for Science and Technology Commercialization
263 Farmington Avenue
Farmington, CT 06030

RE:  ADDITIONAL COSTS APPROVED UNDER RESEARCH AGREEMENT

Dear Mr. Paplauskas:

This letter is in reference to that certain Research Agreement by and between
University of Connecticut Health Center ("UCHC") and Antigenics Inc., a
Delaware corporation ("Antigenics Inc.")(each a "Party" and collectively the
"Parties") dated February 28, 1998 ("Agreement"), as amended by Amendment No.
1 Research Agreement dated April 19, 2002, further amended by Amendment
Agreement dated March 18, 2003, and further amended by Amendment No. 2 to
Research Agreement dated December 30, 2003 (each singly an "Amendment",
collectively the "Agreement"). In accordance with the provisions of Section 5.0
of the Agreement, Antigenics Inc. hereby agrees to pay UCHC an additional
one-time payment in the sum of One Hundred Thirty-Five Thousand dollars
($135,000) for additional costs associated with activities to be performed
under the Agreement in 2005.

Best regards,

/s/ P. Thornton

Peter Thornton
Chief Financial Officer

ANTIGENICS INC., a Delaware corporation

Acknowledged and agreed:

UNIVERSITY OF CONNECTICUT HEALTH CENTER

By:   /s/ Leonard P. Paplauskas
     __________________________

Name:     Leonard P. Paplauskas

Associate Vice President for Research Administration<PAGE>
                                                                     EXHIBIT 4.4

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT"), OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE
TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS IT HAS BEEN REGISTERED UNDER THE ACT
AND SUCH LAWS OR (1) REGISTRATION UNDER APPLICABLE STATE SECURITIES LAWS IS NOT
REQUIRED AND (2) AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY IS FURNISHED
TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED.

NO. [W-#]

                                  VIACELL, INC.

                        WARRANT TO PURCHASE COMMON STOCK

      This certifies that, for value received, [WARRANTHOLDER] (the "Holder") is
entitled to subscribe for and purchase up to [SHARES] shares (subject to
adjustment from time to time pursuant to the provisions of Section 5 hereof) of
fully paid and nonassessable Common Stock of VIACELL, INC., a Delaware
corporation (the "Company"), at the Warrant Price (as defined in Section 2
hereof), subject to the provisions and upon the terms and conditions hereinafter
set forth.

      As used herein, the term "Common Stock" shall mean the Company's presently
authorized Common Stock, $.01 par value per share, and any stock into or for
which such Common Stock may hereafter be converted or exchanged.

      1. Term of Warrant. The purchase or conversion right represented by this
Warrant is exercisable, in whole or in part, at any time during the period
beginning on the date hereof and ending on the earlier of (i) two years from the
date of issuance of this Warrant or (ii) one year following the Company's
initial public offering.

      2. Warrant Price. The initial exercise price of this Warrant is $5.00 per
share, subject to adjustment from time to time pursuant to the provisions of
Section 5 hereof (the "Warrant Price").

      3. Method of Exercise or Conversion; Payment; Issuance of New Warrant.

            (a) Exercise. Subject to Section 1 hereof, the purchase right
represented by this Warrant may be exercised by the holder hereof, in whole or
in part, by the surrender of this Warrant (with the notice of exercise form
attached hereto as Exhibit 1 duly executed) at the principal office of the
Company and by the payment to the Company, by check or wire transfer, of an
amount equal to the then applicable Warrant Price per share multiplied by the
number of shares then being purchased. The Company agrees that the shares so
purchased shall be deemed to be issued to the holder hereof as the record owner
of such shares as of the close of business on the date on which this Warrant
shall have been surrendered and payment made for such shares as aforesaid. In
the event of any exercise of this Warrant, certificates for the shares of stock
so

<PAGE>

purchased shall be delivered to the holder hereof within 15 days thereafter and,
unless this Warrant has been fully exercised or expired, a new Warrant
representing the portion of the shares, if any, with respect to which this
Warrant shall not then have been exercised, shall also be issued to the holder
hereof within such 15 day period.

            (b) Conversion. Subject to Section 1 hereof, the Holder may convert
this Warrant (the "Conversion Right"), in whole or in part, into the number of
shares of Common Stock of the Company calculated pursuant to the following
formula by surrendering this Warrant (with the notice of exercise form attached
hereto as Exhibit 1 duly executed) at the principal office of the Company
specifying the number of shares of Common Stock of the Company, the rights to
purchase which the Holder desires to convert:

                            X =   Y (A - B)
                                  ---------
                                     A
   where: X = the number of shares of Common Stock to be issued to the Holder;
          Y = the number of shares of Common Stock subject to this Warrant for
              which the Conversion Right is being exercised;
          A = the fair market value of one share of Common Stock;
          B = the Warrant Price.

      As used herein, the fair market value of a share of Common Stock shall
mean, with respect to each share of Common Stock, the closing price per share of
the Company's Common Stock on the principal national securities exchange on
which the Common Stock is then listed or admitted to trading or, if not then
listed or admitted to trading on any such exchange, on the NASDAQ National
Market System, or if not then listed or traded on any such exchange or system,
the mean of the bid and asked price per share on NASDAQ Small-Cap Market or in
the sole discretion of a majority of the Board of Directors of the Company, any
other over-the-counter market, including the OTC Bulletin Board, which reports
bid, asked and last sale prices and volume of sales (approval of which will not
be unreasonably withheld by such directors), averaged over the 10 trading days
consisting of the day as of which the current fair market value of Common Stock
is being determined and the 9 consecutive business days prior to such day. If at
any time such quotations are not available, the current fair market value of a
share of Common Stock shall be the highest price per share which the Company
could obtain from a willing buyer (not a current employee or director) for
shares of Common Stock sold by the Company, from authorized but unissued shares,
as determined in good faith by the Board of Directors of the Company, unless (i)
the Company shall become subject to a merger, acquisition or other consolidation
pursuant to which the Company is not the surviving party, in which case the
current fair market value of a share of Common Stock shall be deemed to be the
value received by the holders of the Company's Common Stock for each share of
Common Stock pursuant to the Company's acquisition; or (ii) the Holder shall
exercise its Conversion Right to purchase such shares within 15 days prior to
the closing date of the initial underwritten public offering of the Company's
Common Stock pursuant to a registration statement filed under the Act, in which
case, the fair market value of a share of Common Stock shall be the price per
share at which all registered shares are sold to the public in such offering.
The Company agrees that the shares so converted shall be deemed to be issued to
the holder hereof as the record owner of such shares as of the close of business
on the date on which this Warrant shall have been surrendered as aforesaid. In
the event of any conversion of this Warrant, certificates for the shares of
stock so

<PAGE>

converted shall be delivered to the holder hereof within 15 days thereafter and,
unless this Warrant has been fully converted or expired, a new Warrant
representing the portion of the shares, if any, with respect to which this
Warrant shall not then have been converted, shall also be issued to the holder
hereof within such 15 day period.

      4. Stock Fully Paid; Reservation of Shares. All Common Stock which may be
issued upon the exercise or conversion of this Warrant will, upon issuance, be
fully paid and nonassessable, and free from all taxes, liens and charges with
respect to the issue thereof. During the period within which the rights
represented by this Warrant may be exercised, the Company will at all times have
authorized, and reserved for the purpose of the issuance upon exercise of the
purchase rights evidenced by this Warrant, a sufficient number of shares of its
Common Stock to provide for the exercise of the rights represented by this
Warrant.

      5. Adjustment of Warrant Price and Number of Shares. The kind of
securities purchasable upon the exercise of this Warrant, the Warrant Price and
the number of shares purchasable upon exercise of this Warrant shall be subject
to adjustment from time to time upon the occurrence of certain events as
follows:

            (a) Adjustment for Dilutive Price. If at any time after September
30, 2003 and prior to the expiration of this Warrant, the Company shall issue
any shares of Common Stock, or shall issue any Common Stock Equivalents (as
hereinafter defined), for a consideration per share less than the Warrant Price
in effect immediately prior to the issuance of such Common Stock or Common Stock
Equivalents, the Warrant Price in effect immediately prior to each such issuance
shall be decreased to the amount determined in accordance with the following
formula:

            Warrant Price =  P1Q1 + P2Q2
                             -----------
                                Q1 + Q2
      For purposes of the foregoing formula:
      P1 = Warrant Price in effect immediately prior to such issuance.
      Q1 = Number of shares of Common Stock deemed outstanding (in accordance
           with subparagraph (vi) below) immediately prior to such issuance.
      P2 = Average price per share received by the Company upon such issuance
           (determined in accordance with subparagraphs (iii) and (iv) below).
      Q2 = Number of shares of Common Stock issued or sold, or deemed to have
           been issued or sold (in accordance with subparagraph (iv) below) upon
           such issuance.

      For purpose of any adjustment of the Warrant Price pursuant to this
Section 5(a), the following provisions shall be applicable:

                  (i) "Common Stock Equivalents" means any stock or security
convertible into or exchangeable for Common Stock and any right, warrants or
option to acquire Common Stock or any such convertible or exchangeable security.

                  (ii) The per share consideration for the sale or issuance of
Common Stock shall be the price per share received by the Company before payment
of commissions, discounts and other expenses. The value of any non-cash
consideration received or receivable

<PAGE>

upon the sale or issuance of Common Stock or Common Stock Equivalents shall be
determined in good faith by the Board of Directors of the Company.

                  (iii) In the case of the sale or issuance of Common Stock
Equivalents, the per share consideration shall be determined by dividing the
maximum number of shares of Common Stock issuable with respect to such Common
Stock Equivalents into the aggregate consideration received by the Company upon
the sale of issuance of such Common Stock Equivalents plus the minimum aggregate
amount of any additional consideration receivable by the Company upon the
conversion or exercise of such Common Stock Equivalents. Such maximum number of
shares shall be deemed issued on the earlier of the payment date or the record
date for a distribution of Common Stock Equivalents.

                  (iv) If any Common Stock Equivalents included in adjustments
under this Section 5(a) expire or terminate without the Common Stock to which
they related having been issued, the Warrant Price shall be readjusted to
eliminate the effect of the assumed issuance of such Common Stock. If any Common
Stock Equivalents by their terms provide for subsequent increases in the
additional consideration payable for the related Common Stock or for subsequent
decreases in the number of shares of Common Stock obtainable, upon any such
increase or decrease, the Warrant Price shall be appropriately readjusted to the
extent such Common Stock Equivalents have not then expired or been exercised or
converted. The aggregate increase in the Warrant Price caused by all such
readjustments shall not exceed the decrease in Warrant Price made upon the
issuance of the Common Stock Equivalents to which such readjustment relates.

                  (v) In case the Company shall declare a dividend or make any
other distribution upon any stock of the Company payable in Common Stock or
Common Stock Equivalents, such Common Stock or Common Stock Equivalents shall be
deemed to have been issued or sold without consideration as of the earlier of
the related record or payment date.

                  (vi) The number of shares of Common Stock outstanding at any
point in time shall include all shares then issuable or to become issuable
pursuant to any Common Stock Equivalent then issued or to be issued.

                  (vii) No adjustment to the Warrant Price shall be made for the
following issuances of Common Stock or Common Stock Equivalents: (i) any
dividend or distribution on any Designated Preferred Stock (as defined in the
Company's Fourth Amended and Restated Certificate of Incorporation); (ii) any
stock for which adjustment of the Warrant Price is made pursuant to subsections
5(b) through 5(e) below; (iii) the 1,410,000 shares of Common Stock issuable
upon outstanding warrants as of September 30, 2003; (iv) shares of Series I
Convertible Preferred Stock and/or Common Stock of the Company issued pursuant
to the Stock Purchase Agreement dated as of September 30, 2003 among the Company
and the sellers identified therein; (v) up to an aggregate of 5,192,079 shares
of Common Stock (or such higher number as designated by the Board of Directors)
or options therefor that are issuable to employees, consultants, or scientific
advisory board members of the Company; (vi) the 92,801 shares of Common Stock
issuable upon exercise of outstanding options as of September 30, 2003; (vii)
shares of Common Stock issuable in connection with any equipment leasing
arrangement or technology licensing agreement provided that such issuances are
approved by the Company's

<PAGE>

Board of Directors; (viii) the shares of Common Stock which are issuable upon
conversion of the Designated Preferred Stock; (ix) shares issued in connection
with the acquisition by the Company of any other entity or business; and (x)
shares issued pursuant to a Qualified Public Offering (as defined in subsection
5(a) of the Company's Fourth Amended and Restated Certificate of Incorporation).

            (b) Reclassification, Consolidation or Merger. In case of any
reclassification or change of outstanding securities of the class issuable upon
exercise of this Warrant (other than a change in par value, or from par value to
no par value, or from no par value to par value, or as a result of a subdivision
or combination), or in case of any consolidation or merger of the Company with
or into another corporation, other than a merger with another corporation in
which the Company is a continuing corporation and which does not result in any
reclassification or change of outstanding securities issuable upon exercise of
this Warrant, or in case of any sale of all or substantially all of the assets
of the Company, the Company, or such successor or purchasing corporation, as the
case may be, shall execute a new Warrant, providing that the holder of this
Warrant shall have the right to exercise such new Warrant and procure upon such
exercise, in lieu of each share of Common Stock theretofore issuable upon
exercise of this Warrant, the kind and amount of shares of stock, other
securities, money and property receivable upon such reclassification, change,
consolidation, or merger by a holder of one share of Common Stock. Such new
Warrant shall provide for adjustments which shall be as nearly equivalent as may
be practicable to the adjustments provided for in this Section 5. No
consolidation or merger of the Company with or into another corporation referred
to in the first sentence of this paragraph (b) shall be consummated unless the
successor or purchasing corporation referred to above shall have agreed to issue
a new Warrant as provided in this Section 5. The provisions of this subsection
(c) shall similarly apply to successive reclassification, changes,
consolidations, mergers and transfers.

            (c) Subdivision or Combination of Shares. If the Company at any time
while this Warrant remains outstanding and unexpired shall subdivide or combine
its Common Stock, the Warrant Price shall be proportionately decreased in the
case of a subdivision or increased in the case of a combination.

            (d) Stock Dividends. If the Company at any time while this Warrant
is outstanding and unexpired shall pay a dividend with respect to Common Stock
payable in, or make any other distribution with respect to, Common Stock (except
any distribution specifically provided for in the foregoing subparagraphs (b) or
(c)) then the Warrant Price shall be adjusted, from and after the date of
determination of shareholders entitled to receive such dividend or distribution,
to that price determined by multiplying the Warrant Price in effect immediately
prior to such date of determination by a fraction (x) the numerator of which
shall be the total number of shares of Common Stock outstanding immediately
prior to such dividend or distribution and (y) the denominator of which shall be
the total number of shares of Common Stock outstanding immediately after such
dividend or distribution.

            (e) Adjustment of Number of Shares. Upon each adjustment in the
Warrant Price pursuant to any of Sections 5 (a) through (d), the number of
shares of Common Stock purchasable hereunder shall be adjusted, to the nearest
whole share, to the product obtained by multiplying the number of shares
purchasable immediately prior to such adjustment in the

<PAGE>

Warrant Price by a fraction, the numerator of which shall be the Warrant Price
immediately prior to such adjustment and the denominator of which shall be the
Warrant Price immediately thereafter.

      6. Notice of Adjustments. Whenever any Warrant Price shall be adjusted
pursuant to Section 5 hereof, the Company shall prepare a certificate signed by
its chief financial officer setting forth, in reasonable detail, the event
requiring the adjustment, the amount of the adjustment, the method by which such
adjustment was calculated, the Warrant Price after giving effect to such
adjustment and the number of shares then purchasable upon exercise of this
Warrant, and shall cause copies of such certificate to be mailed (by first class
mail, postage prepaid) to the holder of this Warrant at the address specified in
Section 11(d) hereof, or at such other address as may be provided to the Company
in writing by the holder of this Warrant.

      7. Fractional Shares. No fractional shares of Common Stock will be issued
in connection with any exercise hereunder, but in lieu of such fractional shares
the Company shall make a cash payment therefor upon the basis of the Warrant
Price then in effect.

      8. Compliance with the Act.

            (a) Compliance with the Act. The holder of this Warrant, by
acceptance hereof, agrees that this Warrant and the shares of Common Stock to be
issued upon exercise hereof are being acquired for investment for such holder's
own account and not with a view toward distribution thereof, and that it will
not offer, sell or otherwise dispose of this Warrant or any shares of Common
Stock to be issued upon exercise hereof unless this Warrant has been registered
under the Act and applicable state securities laws or (i) registration under
applicable state securities laws is not required and (ii) an opinion of counsel
satisfactory to the Company is furnished to the Company to the effect that
registration under the Act is not required.

      9. Transfer and Exchange of Warrant.

            (a) Transfer. This Warrant may be transferred or succeeded to by any
person; provided however, that the Company is given written notice by the
transferee at the time of such transfer stating the name and address of the
transferee and identifying the securities with respect to which such rights are
being assigned.

            (b) Exchange. Subject to compliance with the terms hereof, this
Warrant and all rights hereunder are transferable, in whole or in part, at the
office of the Company by the holder hereof in person or by duly authorized
attorney, upon surrender of this Warrant properly endorsed. Each taker and
holder of this Warrant, by taking or holding the same, consents and agrees that
this Warrant, when endorsed in blank, shall be deemed negotiable; provided, that
the last holder of this Warrant as registered on the books of the Company may be
treated by the Company and all persons dealing with this Warrant as the absolute
owner hereof for any purposes and as the person entitled to exercise the rights
represented by this Warrant or to transfer hereof on the books of the Company,
any notice to the contrary notwithstanding, unless and until such holder seeks
to transfer registered ownership of this Warrant on the books of the Company and
such transfer is effected.

<PAGE>

      10. Miscellaneous.

            (a) No Rights as Shareholder. No holder of this Warrant shall be
entitled to vote or receive dividends or be deemed the holder of Common Stock or
any other securities of the Company which may at any time be issuable on the
exercise hereof for any purpose, nor shall anything contained herein be
construed to confer upon the holder of this Warrant, as such, any of the rights
of a shareholder of the Company or any right to vote for the election of
directors or upon any matter submitted to shareholders at any meeting thereof,
or to give or withhold consent to any corporate action (whether upon any
recapitalization, issuance of stock, reclassification of stock, change of par
value or change of stock to no par value, consolidation, merger, conveyance or
otherwise) or to receive notice of meetings, or to receive dividends or
subscription rights or otherwise until this Warrant shall have been exercised
and the shares purchasable upon the exercise hereof shall have become
deliverable, as provided herein.

            (b) Replacement. On receipt of evidence reasonably satisfactory to
the Company of the loss, theft, destruction or mutilation of this Warrant and,
in the case of loss, theft or destruction, on delivery of an indemnity
agreement, or bond reasonably satisfactory in form and amount to the Company or,
in the case of mutilation, on surrender and cancellation of this Warrant, the
Company, at its expense, will execute and deliver, in lieu of this Warrant, a
new warrant of like tenor.

            (c) Notice of Capital Changes. In case:

                  (i) the Company shall declare any dividend or distribution
payable to the holders of its Common Stock;

                  (ii) there shall be any capital reorganization or
reclassification of the capital stock of the Company, or consolidation or merger
of the Company with, or sale of all or substantially all of its assets to,
another corporation or business organization; or

                  (iii) there shall be a voluntary or involuntary dissolution,
liquidation or winding up of the Company;

then, in any one or more of said cases, the Company shall give the holder of
this Warrant written notice, in the manner set forth in subparagraph (d) below,
of the date on which a record shall be taken for such dividend, or distribution
or for determining shareholders entitled to vote upon such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation or
winding up and of the date when any such transaction shall take place, as the
case may be. Such written notice shall be given at least 30 days prior to the
transaction in question and not less than 20 days prior to the record date in
respect thereof.

            (d) Notice. Any notice given to either party under this Warrant
shall be in writing, and any notice hereunder shall be deemed to have been given
upon the earlier of delivery thereof by hand delivery, by courier, or by
standard form of telecommunication or three (3) business days after the mailing
thereof if sent registered mail with postage prepaid, addressed to the Company
at its principal executive offices and to the holder at its address set forth in
the Company's books and records or at such other address as the holder may have
provided to the Company in writing.

<PAGE>

            (e) No Impairment. The Company will not, by amendment of its Fourth
Restated Certificate of Incorporation or through any reorganization, transfer of
assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed hereunder by the Company, but will
at all times in good faith assist in the carrying out of all the provisions in
the Warrant.

            (f) Governing Law. This Warrant shall be governed by and construed
under the laws of the Commonwealth of Massachusetts.

            [THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.]

<PAGE>

      IN WITNESS WHEREOF, this Warrant is executed as of this 26th day of
January, 2005.

                        VIACELL, INC.

                        By:
                             ------------------------------------------------
                        Name:  Marc D. Beer
                        Title: Chief Executive Officer

<PAGE>

                                                                       EXHIBIT 1

                               NOTICE OF EXERCISE

TO:   VIACELL, INC.

      1.    Check Box that Applies:

      [] The undersigned hereby elects to purchase __________ shares of Common
Stock of VIACELL, INC. pursuant to the terms of the attached Warrant, and
tenders herewith payment of the purchase price of such shares in full.

      [] The undersigned hereby elects to convert the attached warrant into
__________ shares of Common Stock of VIACELL, INC. pursuant to the terms of the
attached Warrant.

      2. Please issue a certificate or certificates representing said shares of
Common Stock in the name of the undersigned or in such other name as is
specified below:

                 -----------------------------------------------

                                    (Name)

                 -----------------------------------------------

                 -----------------------------------------------

                                    (Address)

      3. The undersigned represents that the aforesaid shares of Common Stock
are being acquired for the account of the undersigned for investment and not
with a view to, or for resale in connection with, the distribution thereof and
that the undersigned has no present intention of distributing or reselling such
shares.

                                          --------------------------------------
                                          Signature

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]